Figure 4.
Analysis of the characteristics of immunotherapy biomarkers in early stage and advanced-stage NSCLCs. TMB-H, high tumor mutation burden; TMB-L, low tumor mutation burden.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.